Hamid Emamekhoo

Also affiliated with University of Wisconsin Carbone Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile

0.905Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer

The Oncologist(2020)10.1634/theoncologist.2019-0851

Top 22%

0.905DataRank

Top 22%21 citations

Petros Grivas, Qi-En Wang, Amir Mortazavi, Hamid Emamekhoo, Sheldon L. Holder +9 more

Papers

Driven by 25 papers — median percentile 78. Top paper: “Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study”.

Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study

The Lancet Oncology(2024)10.1016/s1470-2045(24)00211-0

N/A

1.9DataRank · unranked

86 citations

Se-Eun Kim, Viraj A. Master, David H. McDermott, Lauren C. Harshman, Suzanne Cole +40 more

Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma

JAMA Oncology(2021)10.1001/jamaoncol.2021.3441

N/A

1.6DataRank · unranked

45 citations

Paul Frankel, Amir Mortazavi, Matthew I. Milowsky, Ulka N. Vaishampayan, Mamta Parikh +15 more

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2021-004198

N/A

1.2DataRank · unranked

52 citations

Jens C. Eickhoff, Ellen Wargowski, Laura E. Johnson, Christos E. Kyriakopoulos, Hamid Emamekhoo +4 more

Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma

Molecular Oncology(2021)10.1002/1878-0261.12931

N/A

0.959DataRank · unranked

22 citations

Jennifer L. Schehr, Hamid Emamekhoo, Benjamin K. Gibbs, Tamara S. Rodems, Matthew C. Mannino +16 more

Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-008067

N/A

0.937DataRank · unranked

36 citations

Hamid Emamekhoo, Jens C. Eickhoff, Christos E. Kyriakopoulos, Ellen Wargowski, Tommaso P Tonelli +3 more

Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer

The Oncologist(2020)10.1634/theoncologist.2019-0851

Top 22%

0.905DataRank

Top 22%21 citations

Petros Grivas, Qi-En Wang, Amir Mortazavi, Hamid Emamekhoo, Sheldon L. Holder +9 more

Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study

Cancer(2021)10.1002/cncr.34057

N/A

0.670DataRank · unranked

86 citations

Nicholas Henderson, Marihella James, Divya Natesan, Dory Freeman, Amanda Nizam +31 more

Getting ready for real‐world use of electronic patient‐reported outcomes (ePROs) for patients with cancer: A National Comprehensive Cancer Network ePRO Workgroup paper

Cancer(2023)10.1002/cncr.34844

N/A

0.483DataRank · unranked

24 citations

Waddah Arafat, Ashish Atreja, Lauren B. Bruckner, Hamid Emamekhoo, Tricia Heinrichs +6 more

High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes

Cancer Discovery(2025)10.1158/2159-8290.cd-24-1509

N/A

0.425DataRank · unranked

16 citations

Jamie M. Sperger, Amy K. Taylor, Katharine E. Tippins, Shannon R. Reese, V. Carreño +31 more

Core biopsy (bx) accuracy and safety of biopsy and preoperative immunotherapy in predicting histological subtype and nuclear grade in ECOG-ACRIN EA8143 perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4541

N/A

0.104DataRank · unranked

1 citations

Se Eun Kim, David F. McDermott, Viraj A. Master, Sabina Signoretti, Mahmut Akgül +13 more

Prognostic value of integrated liquid biopsies in patients (pts) with metastatic urothelial cancer (mUC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.547

N/A

0.104DataRank · unranked

1 citations

Hamid Emamekhoo, Katherine R. Kaufmann, Petros Grivas, Moshe Chaim Ornstein, Iris Yeong- Fung Sheng +9 more

A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4507

N/A

0.104DataRank · unranked

1 citations

Amir Mortazavi, Matthew I. Milowsky, Ulka N. Vaishampayan, Mamta Parikh, Yung Lyou +15 more

Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels

Nature Communications(2025)10.1038/s41467-025-64153-z

N/A

0DataRank · unranked

8 citations

Marina N. Sharifi, Jamie M. Sperger, Matthew R. Chrostek, Matthew L. Bootsma, Shannon R. Reese +22 more

Investigating clinical associations between genomic alterations and prostate cancer lineage states using circulating tumor cell RNA sequencing.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.5_suppl.256

N/A

0DataRank · unranked

0 citations

Joshua M. Lang, Marina N. Sharifi, Jamie M. Sperger, Shannon R. Reese, Amy K. Taylor +8 more

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.tps760

N/A

0DataRank · unranked

13 citations

Karla V. Ballman, Atish D. Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen +7 more

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps5100

N/A

0DataRank · unranked

9 citations

Karla V. Ballman, Atish D. Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen +8 more

Phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) and nivolumab (Nivo) in patients (pts) with nonmetastatic, PSA-recurrent prostate cancer (PCa).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.tps273

N/A

0DataRank · unranked

2 citations

Christos E. Kyriakopoulos, Glenn Liu, Douglas G. McNeel, Hamid Emamekhoo

Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study

European Journal of Nuclear Medicine and Molecular Imaging(2021)10.1007/s00259-021-05650-3

N/A

0DataRank · unranked

28 citations

Daniel T Huff, Andrej Studen, Katarina Zevnik, Žan Klaneček, Hamid Emamekhoo +4 more

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.tps366

N/A

0DataRank · unranked

26 citations

Karla V. Ballman, Atish D. Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen +8 more

A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer

Journal of Clinical Investigation(2022)10.1172/jci161858

N/A

0DataRank · unranked

33 citations

Jamie M. Sperger, Jennifer L. Schehr, Rana R. McKay, Hamid Emamekhoo, Anupama Singh +34 more

A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps3174

N/A

0DataRank · unranked

5 citations

Paul Frankel, Jan H. Beumer, Naoko Takebe, Ming Yin, Hamid Emamekhoo +4 more

Single cell phenotyping of PDL1 and HLA1 on circulating tumor cells (CTC) in clear cell renal cell carcinoma (ccRCC) on systemic treatment with immunotherapy (IO) and vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKI).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.381

N/A

0DataRank · unranked

0 citations

Matthew C. Mannino, Matthew L. Bootsma, Rory M. Bade, Meghan Wells, Jennifer L. Schehr +5 more

Fragmentomic analysis of circulating tumor DNA-targeted cancer panels

Annals of Oncology(2023)10.1016/j.annonc.2023.06.001

N/A

0DataRank · unranked

67 citations

Marina N. Sharifi, Jamie M. Sperger, Yue Shi, Matti Annala, Matthew L. Bootsma +29 more

Neutrophil‐to‐eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti‐PD‐1 therapy

Pigment Cell & Melanoma Research(2023)10.1111/pcmr.13109

N/A

0DataRank · unranked

24 citations

Yeonhee Park, Yusuf M. Mohamoud, Dahlia Tesfamichael, Hamid Emamekhoo, Alexander Birbrair +3 more

Association of emergent neuroendocrine prostate cancer detected by liquid biopsies with survival and treatment resistance.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.247

N/A

0DataRank · unranked

1 citations

Jamie M. Sperger, Marina N. Sharifi, Yue Shi, Charlotte N. Stahlfeld, Jennifer L. Schehr +9 more

Hamid Emamekhoo

Indexed papers

Top data-sharing exemplar

Papers